PT2846770T - Administração intratecal de inibidores de mtor para a terapia de doenças neurodegenerativas, neuroinflamatórias e neuro-oncológicas - Google Patents

Administração intratecal de inibidores de mtor para a terapia de doenças neurodegenerativas, neuroinflamatórias e neuro-oncológicas

Info

Publication number
PT2846770T
PT2846770T PT13730352T PT13730352T PT2846770T PT 2846770 T PT2846770 T PT 2846770T PT 13730352 T PT13730352 T PT 13730352T PT 13730352 T PT13730352 T PT 13730352T PT 2846770 T PT2846770 T PT 2846770T
Authority
PT
Portugal
Prior art keywords
neurooncologic
neuroinflammatory
neurodegenerative
therapy
diseases
Prior art date
Application number
PT13730352T
Other languages
English (en)
Inventor
Cassano Tommaso
Giovagnoli Stefano
Magini Alessandro
Emiliani Carla
Original Assignee
Dolcetta Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dolcetta Diego filed Critical Dolcetta Diego
Publication of PT2846770T publication Critical patent/PT2846770T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT13730352T 2012-05-11 2013-05-10 Administração intratecal de inibidores de mtor para a terapia de doenças neurodegenerativas, neuroinflamatórias e neuro-oncológicas PT2846770T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000814A ITMI20120814A1 (it) 2012-05-11 2012-05-11 Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche

Publications (1)

Publication Number Publication Date
PT2846770T true PT2846770T (pt) 2018-10-15

Family

ID=46582908

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13730352T PT2846770T (pt) 2012-05-11 2013-05-10 Administração intratecal de inibidores de mtor para a terapia de doenças neurodegenerativas, neuroinflamatórias e neuro-oncológicas

Country Status (10)

Country Link
US (2) US20150132397A1 (pt)
EP (1) EP2846770B1 (pt)
CN (1) CN104427975A (pt)
DK (1) DK2846770T3 (pt)
ES (1) ES2686561T3 (pt)
IN (1) IN2014MN02475A (pt)
IT (1) ITMI20120814A1 (pt)
PL (1) PL2846770T3 (pt)
PT (1) PT2846770T (pt)
WO (1) WO2013168131A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104490873A (zh) * 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物
GB2564383B (en) * 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
CN109406650A (zh) * 2018-10-25 2019-03-01 美康生物科技股份有限公司 用于准确测定人全血中四种免疫抑制剂类药物浓度的试剂盒及检测方法
CN109187839A (zh) * 2018-10-25 2019-01-11 美康生物科技股份有限公司 准确测定人全血中四种免疫抑制剂类药物浓度的试剂盒及检测方法
IT202000007228A1 (it) * 2020-04-06 2021-10-06 Diego Dolcetta SOMMINISTRAZIONE DI INIBITORI DI mTOR NEL SISTEMA NERVOSO CENTRALE
KR20230037647A (ko) * 2020-07-14 2023-03-16 얀센 파마슈티카 엔.브이. 타우병증 또는 아밀로이드성 질환을 검출하기 위한 혈액-기반 검정
TW202233666A (zh) * 2020-10-26 2022-09-01 比利時商健生藥品公司 減少人類對象中之tau的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003272539A1 (en) * 2002-09-17 2004-04-08 New York University Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
ATE520400T1 (de) * 2002-11-21 2011-09-15 Genzyme Corp Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
US20080207671A1 (en) * 2006-07-31 2008-08-28 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
US20090274764A1 (en) * 2008-04-30 2009-11-05 Do Hiep Q Hollow Foam Beads for Treatment of Glioblastoma
CA2768710A1 (en) * 2009-07-24 2011-01-27 Institut National De La Recherche Scientifique Combinations of curcuminoids and mtor inhibitors for the treatment of tauopathies

Also Published As

Publication number Publication date
WO2013168131A1 (en) 2013-11-14
ITMI20120814A1 (it) 2013-11-12
US20160324770A1 (en) 2016-11-10
US20150132397A1 (en) 2015-05-14
IN2014MN02475A (pt) 2015-07-10
ES2686561T3 (es) 2018-10-18
DK2846770T3 (en) 2018-09-17
PL2846770T3 (pl) 2019-02-28
CN104427975A (zh) 2015-03-18
EP2846770A1 (en) 2015-03-18
EP2846770B1 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
IL238575A0 (en) Systems and methods for administering drugs to the lung
EP3004083A4 (en) COMPOUNDS FOR THE TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
IL263661A (en) Combination therapy for the treatment of glioblastoma
EP2726141A4 (en) DEVICE, SYSTEM AND METHODS FOR ORAL DELIVERY OF THERAPEUTIC COMPOUNDS
EP3038647A4 (en) Combination therapy for the treatment of glioblastoma
HK1213794A1 (zh) 聯合治療及用於治療脫髓鞘病症的用途
HK1206937A1 (en) Methods of administering pirfenidone therapy
EP2806926A4 (en) SYSTEMS AND METHODS FOR DISPENSING RESPIRATORY THERAPY
EP3068353A4 (en) Systems and methods for subretinal delivery of therapeutic agents
EP3010486A4 (en) Chemical structures for localized delivery of therapeutic agents
EP2968739A4 (en) Infusion systems for the controlled delivery of therapeutic agents
PT2846770T (pt) Administração intratecal de inibidores de mtor para a terapia de doenças neurodegenerativas, neuroinflamatórias e neuro-oncológicas
EP2906583A4 (en) PEPTIDES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP2974730A4 (en) MEDICINES FOR RESPIRATORY DISEASES
HK1219224A1 (zh) 角結膜病症的治療劑
EP3103446A4 (en) Pharmaceutical preparation for preventing and treating progressive myopia
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
HK1218882A1 (zh) 用於治療神經退化疾病和其它疾病的組合治療劑和方法
EP3075380A4 (en) Drug for treating vertebrae cervicales and lumber diseases
EP3049075A4 (en) Laquinimod combination therapy for treatment of multiple sclerosis
PT2922541T (pt) Piridil-hidrazonas para o tratamento de tuberculose e doenças relacionadas
AU2012902640A0 (en) Dosage Regime for Animal Treatment